Deciding on the best pharmacotherapy for advanced triple-negative breast cancer: expert guidance

Expert Opin Pharmacother. 2022 Nov;23(16):1765-1770. doi: 10.1080/14656566.2022.2139176. Epub 2022 Nov 3.

Carla Corvaja^{1

2}, Beatrice Taurelli Salimbeni^{2

3}, Eleonora Nicolò^{2

4}, Fabio Puglisi^{1

5}, Giuseppe Curigliano^{2

4}

¹ Department of Medicine, University of Udine, Udine, Italy.
² Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.
³ Department of Clinical and Molecular Medicine, Oncology Unit, "la Sapienza" University of Rome, Azienda Ospedaliera Sant'Andrea, Rome, Italy.
⁴ Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy.
⁵ Department of Medicine, University of Udine, and Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy.

No abstract available

Keywords: ADC; BRCA1/2; HER2-low breast cancer; TNBC; immunotherapy; targeted therapies.

Publication types